<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04228432</url>
  </required_header>
  <id_info>
    <org_study_id>19 SEIN 14</org_study_id>
    <nct_id>NCT04228432</nct_id>
  </id_info>
  <brief_title>E-monitoring of Patients Under Adjuvant Hormonotherapy for Breast Cancer.</brief_title>
  <acronym>EPOPEE</acronym>
  <official_title>E-monitoring of Patients Under Adjuvant Hormonotherapy for Breast Cancer: Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a monocentric, prospective cohort study evaluating the feasibility of an E-monitoring&#xD;
      protocol in patients with breast cancer treated by adjuvant hormonotherapy .&#xD;
&#xD;
      45 patients will be included.&#xD;
&#xD;
      Patients will be followed during 6 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 28, 2020</start_date>
  <completion_date type="Actual">July 21, 2021</completion_date>
  <primary_completion_date type="Actual">July 21, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patients who do not fail the E-Monitoring protocol</measure>
    <time_frame>6 months per patient</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of medical consultations required over 6 months</measure>
    <time_frame>6 months per patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of hormonotherapy adherence evaluated by the GIRERD questionnaire</measure>
    <time_frame>6 months per patient</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Patients with breast cancer treated by adjuvant hormonotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dedicated and coordinated monitoring</intervention_name>
    <description>Coordinated monitoring performed by a dedicated nurse: consultation before hormonotherapy initiation&#xD;
Monitoring at home over a period of 6 months using an e-monitoring tool: assessment of adverse events and completion of GIRERD questionnaire at week 3 and week 6.</description>
    <arm_group_label>Patients with breast cancer treated by adjuvant hormonotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient treated for hormone-dependent localized breast cancer with adjuvant HT&#xD;
             (tamoxifen or anti-aromatase +/- LHRH agonist)&#xD;
&#xD;
          2. Patient equipped with a computer or tablet computer and an internet connection at home&#xD;
&#xD;
          3. Age &gt; 18 years old&#xD;
&#xD;
          4. Patient affiliated to the french social security system&#xD;
&#xD;
          5. Patient who has signed informed consent before inclusion in the study and before any&#xD;
             specific procedures for the study&#xD;
&#xD;
          6. Women of childbearing age should have effective contraception under hormonotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient with breast cancer who does not require adjuvant hormonotherapy&#xD;
&#xD;
          2. Patient with metastatic breast cancer&#xD;
&#xD;
          3. Any psychological, familial, geographic or social situation, according to the judgment&#xD;
             of investigator, potentially preventing the provision of informed consent or&#xD;
             compliance to study procedure&#xD;
&#xD;
          4. Patient previously treated for breast cancer (infiltrating or in-situ) with adjuvant&#xD;
             HT or not&#xD;
&#xD;
          5. Patient protected by law.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer Toulouse Oncopole</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 10, 2020</study_first_submitted>
  <study_first_submitted_qc>January 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2020</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Hormonotherapy</keyword>
  <keyword>E-monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

